224 related articles for article (PubMed ID: 18550720)
1. Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer.
Yamashita H; Nishio M; Toyama T; Sugiura H; Kondo N; Kobayashi S; Fujii Y; Iwase H
Endocr Relat Cancer; 2008 Sep; 15(3):755-63. PubMed ID: 18550720
[TBL] [Abstract][Full Text] [Related]
2. Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Motomura K; Ishitobi M; Komoike Y; Koyama H; Nagase H; Inaji H; Noguchi S
Oncology; 2010; 79(1-2):55-61. PubMed ID: 21071990
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
4. Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer.
Yamashita H; Takahashi S; Ito Y; Yamashita T; Ando Y; Toyama T; Sugiura H; Yoshimoto N; Kobayashi S; Fujii Y; Iwase H
Cancer Sci; 2009 Nov; 100(11):2028-33. PubMed ID: 19659610
[TBL] [Abstract][Full Text] [Related]
5. Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen.
Glaros S; Atanaskova N; Zhao C; Skafar DF; Reddy KB
Mol Endocrinol; 2006 May; 20(5):996-1008. PubMed ID: 16455819
[TBL] [Abstract][Full Text] [Related]
6. Reactive oxygen species induce phosphorylation of serine 118 and 167 on estrogen receptor alpha.
Weitsman GE; Weebadda W; Ung K; Murphy LC
Breast Cancer Res Treat; 2009 Nov; 118(2):269-79. PubMed ID: 18941890
[TBL] [Abstract][Full Text] [Related]
7. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
8.
Ishida N; Baba M; Hatanaka Y; Hagio K; Okada H; Hatanaka KC; Togashi K; Matsuno Y; Yamashita H
Oncotarget; 2018 Apr; 9(25):17711-17724. PubMed ID: 29707142
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients.
Jiang J; Sarwar N; Peston D; Kulinskaya E; Shousha S; Coombes RC; Ali S
Clin Cancer Res; 2007 Oct; 13(19):5769-76. PubMed ID: 17908967
[TBL] [Abstract][Full Text] [Related]
10. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
11. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
Kruger DT; Alexi X; Opdam M; Schuurman K; Voorwerk L; Sanders J; van der Noort V; Boven E; Zwart W; Linn SC
Int J Cancer; 2020 Apr; 146(8):2348-2359. PubMed ID: 31490549
[TBL] [Abstract][Full Text] [Related]
12. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
[TBL] [Abstract][Full Text] [Related]
13. Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.
Busch S; Sims AH; Stål O; Fernö M; Landberg G
Cancer Res; 2015 Apr; 75(7):1457-69. PubMed ID: 25833830
[TBL] [Abstract][Full Text] [Related]
14. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.
Plaza-Menacho I; Morandi A; Robertson D; Pancholi S; Drury S; Dowsett M; Martin LA; Isacke CM
Oncogene; 2010 Aug; 29(33):4648-57. PubMed ID: 20531297
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
16. Interactions between MAP kinase and oestrogen receptor in human breast cancer.
McGlynn LM; Tovey S; Bartlett JM; Doughty J; Cooke TG; Edwards J
Eur J Cancer; 2013 Apr; 49(6):1176-86. PubMed ID: 23265704
[TBL] [Abstract][Full Text] [Related]
17. Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo.
Murphy L; Cherlet T; Adeyinka A; Niu Y; Snell L; Watson P
Clin Cancer Res; 2004 Feb; 10(4):1354-9. PubMed ID: 14977836
[TBL] [Abstract][Full Text] [Related]
18. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
Fukui F; Hayashi SI; Yamaguchi Y
J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
[TBL] [Abstract][Full Text] [Related]
19. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
20. AKT activation predicts outcome in breast cancer patients treated with tamoxifen.
Kirkegaard T; Witton CJ; McGlynn LM; Tovey SM; Dunne B; Lyon A; Bartlett JM
J Pathol; 2005 Oct; 207(2):139-46. PubMed ID: 16088978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]